Sanayama Hidenori, Ito Kiyonori, Ookawara Susumu, Uemura Takeshi, Sakiyama Yoshio, Sugawara Hitoshi, Tabei Kaoru, Igarashi Kazuei, Soda Kuniyasu
Division of Neurology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, Saitama 330-8503, Japan.
Division of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, Saitama 330-8503, Japan.
Biomedicines. 2023 May 9;11(5):1403. doi: 10.3390/biomedicines11051403.
Early diagnosis and therapeutic intervention improve the quality of life and prognosis of patients with sarcopenia. The natural polyamines spermine and spermidine are involved in many physiological activities. Therefore, we investigated blood polyamine levels as a potential biomarker for sarcopenia. Subjects were Japanese patients >70 years of age who visited outpatient clinics or resided in nursing homes. Sarcopenia was determined based on muscle mass, muscle strength, and physical performance according to the criteria of the Asian Working Group for Sarcopenia (2019). The analysis included 182 patients (male: 38%, age: 83 [76-90] years). Spermidine levels were higher ( = 0.002) and the spermine/spermidine ratio was lower ( < 0.001) in the sarcopenia group than in the non-sarcopenia group. Polyamine concentration analysis showed that the odds ratios for age and spermidine changed in parallel with sarcopenia progression, and the odds ratio for the spermine/spermidine ratio changed inversely with the degree of sarcopenia progression. Additionally, when the odds ratio was analyzed with spermine/spermidine instead of polyamine concentrations, only for spermine/spermidine, the odds ratio values varied in parallel with the progression of sarcopenia. Based on the present data, we believe that the blood spermine/spermidine ratio may be a diagnostic indicator of risk for sarcopenia.
早期诊断和治疗干预可改善肌肉减少症患者的生活质量和预后。天然多胺精胺和亚精胺参与许多生理活动。因此，我们研究了血液多胺水平作为肌肉减少症的潜在生物标志物。研究对象为年龄大于70岁的日本门诊患者或养老院居民。根据亚洲肌肉减少症工作组（2019年）的标准，基于肌肉质量、肌肉力量和身体表现来确定肌肉减少症。分析纳入了182例患者（男性：38%，年龄：83[76 - 90]岁）。肌肉减少症组的亚精胺水平较高（P = 0.002），精胺/亚精胺比值较低（P < 0.001），高于非肌肉减少症组。多胺浓度分析表明，年龄和亚精胺的优势比随肌肉减少症进展呈平行变化，精胺/亚精胺比值的优势比与肌肉减少症进展程度呈反向变化。此外，当用精胺/亚精胺而非多胺浓度分析优势比时，仅精胺/亚精胺的优势比值随肌肉减少症进展而平行变化。基于目前的数据，我们认为血液精胺/亚精胺比值可能是肌肉减少症风险的诊断指标。
